Advanced search

News (407)

Transcript : Ultragenyx Pharmaceutical Inc., Q1 2024 Earnings Call, May 02, 2024	05-02
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update	05-02	GL
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease	04-30	GL
Transcript : Ultragenyx Pharmaceutical Inc. - Special Call	04-15
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:00 AM	03-13
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 04:20 PM	03-12
Ultragenyx to Participate at Investor Conferences in March	02-27	GL
Transcript : Ultragenyx Pharmaceutical Inc., Q4 2023 Earnings Call, Feb 15, 2024	02-15
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update	02-15	GL
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update	02-15	AQ
Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)	02-06	GL
Transcript : Ultragenyx Pharmaceutical Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 03:00 PM	01-08
Ultragenyx Reports Preliminary 2023 Revenue, Guidance for 2024 Revenue and Cash Usage, Pipeline Updates and 2024 Milestones	01-08	AQ
Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones	01-07	AQ
Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones	01-07	GL
Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference	01-02	GL
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-29-2023 10:00 AM	11-29
Ultragenyx to Participate at Investor Conferences in November	11-20	GL
Ultragenyx to Participate at Investor Conferences in November	11-20	AQ
Transcript : Ultragenyx Pharmaceutical Inc. Presents at 14th Annual Jefferies London Healthcare Conference 2023, Nov-14-2023 12:30 PM	11-14
Ultragenyx to Participate in the Jefferies London Healthcare Conference	11-07	GL
Ultragenyx to Participate in the Jefferies London Healthcare Conference	11-07	AQ
Transcript : Ultragenyx Pharmaceutical Inc., Q3 2023 Earnings Call, Nov 02, 2023	11-02
Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update	11-02	GL
Transcript : Ultragenyx Pharmaceutical Inc. - Analyst/Investor Day	23-10-16
Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (OI), Angelman Syndrome (AS) and Wilson Disease	23-10-16	GL
Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (OI), Angelman Syndrome (AS) and Wilson Disease	23-10-16	AQ
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 08:50 AM	23-09-12
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Citi 18th Annual BioPharma Conference, Sep-06-2023 08:50 AM	23-09-06
Ultragenyx to Participate at Investor Conferences in September	23-08-31	GL
Ultragenyx to Participate at Investor Conferences in September	23-08-31	AQ
Transcript : Ultragenyx Pharmaceutical Inc., Q2 2023 Earnings Call, Aug 03, 2023	23-08-03
Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update	23-08-03	GL
Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update	23-08-03	AQ
Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy	23-07-12	GL
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-12-2023 03:20 PM	23-06-12
Ultragenyx to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference	23-06-07	GL
Transcript : Ultragenyx Pharmaceutical Inc. - Special Call	23-06-05
Ultragenyx Pharmaceutical : Issues 2022 Environmental, Social and Governance (ESG) Report	23-05-24	PU
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Bank of America Securities 2023 Healthcare Conference, May-10-2023 09:20 AM	23-05-10
Ultragenyx to Present at Bank of America’s 2023 Health Care Conference	23-05-05	GL
Ultragenyx to Present at Bank of America’s 2023 Health Care Conference	23-05-05	AQ
Transcript : Ultragenyx Pharmaceutical Inc., Q1 2023 Earnings Call, May 04, 2023	23-05-04
Ultragenyx Reports First Quarter 2023 Financial Results and Corporate Update	23-05-04	GL
Transcript : Ultragenyx Pharmaceutical Inc. Presents at Guggenheim Healthcare Talks Genomic Medicines and Rare Disease Days, Apr-03-2023 10:45 AM	23-04-03

1234NextSee all

Companies (2)

FIYTA PRECISION TECHNOLOGY CO., LTD. 539 M $

FIYTA Precision Technology Co., Ltd., formerly FIYTA HOLDINGS LTD., is a China-based company mainly engaged in the research and development, design, manufacture, sales and repairing of watches and the related parts and accessories. The Company's core busi ...

FIYTA PRECISION TECHNOLOGY CO., LTD. 539 M $

Insiders

Emil Kakkis

Emil D. Kakkis founded Ultragenyx Pharmaceutical, Inc. and Everylife Foundation for Rare Diseases. Dr. Kakkis occupies the position of President, Chief Executive Officer & Director at Ultragenyx Pharmaceutical, Inc. Dr. Kakkis is also on the board of Emil Kakkis & Jenny Soriano Living Trust and Odylia Therapeutics and President of Everylife Foundation for Rare Diseases. In his past career Dr. Kakkis was Chief Medical Officer & Senior Vice President for BioMarin Pharmaceutical, Inc. and Assistant Professor at Harbor-UCLA Medical Center. Dr. Kakkis received an undergraduate degree from Pomona College and a doctorate from David Geffen School of Medicine.

Emil Ivaner

Emil Wikström

Emil Boldus

Emil Boldus served as the Chairman-Supervisory Board at Generali Asigurari SA.

Emil Rathenau is the founder of AEG Power Solutions BV and 3W Power S.A.
His founding positions include the job function code "FOU" for both firms.
No titles are mentioned.

Emil Beg

Emil Szutkiewicz

No results for this search